An announcement from Esperion ( (ESPR) ) is now available.
On April 1, 2025, Esperion Therapeutics announced the appointment of Robert E. Hoffman as an independent director and Chairperson of the Audit Committee, effective May 29, 2025. This follows the resignation of board members Nicole Vitullo and Antonio M. Gotto, Jr., effective June 1, 2025. Hoffman’s extensive experience in the biopharmaceutical sector is expected to support Esperion’s growth and commercialization efforts, particularly in expanding its pipeline of ACLY inhibitors.
More about Esperion
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing new medicines to address unmet needs for patients and healthcare professionals, particularly those at risk for cardiovascular disease. The company is known for its FDA-approved oral, once-daily, non-statin medicines targeting elevated low-density lipoprotein cholesterol (LDL-C) and is advancing its pipeline with ATP citrate lyase inhibitors (ACLYi).
YTD Price Performance: -34.55%
Average Trading Volume: 4,224,389
Technical Sentiment Signal: Buy
Current Market Cap: $284.9M
For an in-depth examination of ESPR stock, go to TipRanks’ Stock Analysis page.